

Pharmacy Formulary Updates for June 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in June 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
guanidine	T1
Elzonris	MB
Firdapse	T2;PA
Xepi	T3;QL
Krintafel	T1;QL
Arakoda	NC
Prograf granules	T3
Herceptin Hylecta	MB
Tirosint-Sol	T3
Lotemax SM	NC
Dsuvia	MB
albuterol sulfate HFA inhaler (Proventil HFA)	NC;QL
solifenacin succinate	T2
Vesicare	NC
erythromycin ethylsuccinate 400 mg/5 mL suspension	T2
Eryped 400 mg/5 mL suspension	NC
acyclovir 5% cream	T2;QL
Zovirax 5% cream	NC;QL
deferasirox	T2
Exjade	NC

Key:

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy